Understanding how immune and stromal factors affect prostate cancer progression and treatment response
Official title: Project 1: Investigation of immune and stromal factors that promote prostate adenocarcinoma progression and castration response
Funded at Columbia University Health Sciences · NIH-11078868 · Data updated 2026-11-12
This study is looking at how prostate cancer cells interact with their surroundings, especially the immune system and other supporting cells, to better understand how the disease grows and responds to treatments, which could help create more personalized and effective therapies for patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 1, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $487,709 |
| NIH project number | 5P01CA265768-04 |
| Project ID | NIH-11078868 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with advanced prostate cancer, particularly those who have undergone androgen receptor pathway inhibition.
✕Less likely to help
Patients with early-stage prostate cancer or those not undergoing treatment may not receive direct benefits from this research.
What this research studies
This research investigates the interactions between prostate cancer cells and their surrounding environment, focusing on immune and stromal factors that influence disease progression and response to treatment. By utilizing advanced single-cell sequencing technologies, the study aims to uncover the complexities of the tumor microenvironment and how it changes during cancer progression and treatment with androgen receptor inhibitors. Patients may benefit from insights gained that could lead to improved therapeutic strategies tailored to their specific cancer characteristics.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for advanced prostate cancer by targeting the tumor microenvironment.
How similar studies have gone: Other research has shown promising results in understanding tumor microenvironment interactions, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Sawyers, Charles L. — Columbia University Health Sciences
- Study coordinator: Sawyers, Charles L.
Related research
Other NIH-funded projects on the same topics.
-
Immune and tumor environment factors driving prostate cancer progression and response to androgen deprivation
A large NIH grant is exploring how immune cells and the tumor environment affect prostate cancer growth and response to androgen-suppressing treatments.
-
Natural products to block IL-8 signaling and prevent Barrett's Esophagus from turning into esophageal cancer
A搜索-friendly plan to use safe natural compounds to interrupt a key inflammatory signal (IL-8) and stop Barrett’s esophagus from turning into esophageal cancer in people with GERD.
-
Understanding how CDH1 loss drives aggressive stomach cancer and how to target it
Researchers are studying why certain advanced stomach cancers grow and spread, with a focus on CDH1 inactivation and related pathways to find ways to improve treatment for patients.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Fibrin-rich tumor stroma as a new driver of immune response in pancreatic cancer
This grant explores how fibrin-involved tumor surroundings in pancreatic cancer might affect immune therapy, with the goal of making treatments work better for patients.
-
TREM2+ macrophages and liver metastases in pancreatic cancer
Researchers are studying immune cells in liver metastases from pancreatic cancer to understand how they influence the cancer’s spread and more effective treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.